Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.42 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.42 |
| ▸ | SPHK1 | Q9NYA1 | 3/20 | 0.42 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.42 |
| ▸ | MET | P08581 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7247863 | 0.93 | LTA4H (0.48) | KDM4EMAOBLTA4HTMEM97SIGMAR1 | |
| SCHEMBL7243458 | 0.89 | TMEM97 (0.53) | KDM4EHRH3TMEM97SIGMAR1ADRA1D | |
| SCHEMBL7245268 | 0.87 | TMEM97 (0.52) | HRH3TMEM97SIGMAR1ADRA1DADRA1A | |
| Bromide SCHEMBL5888803 | 0.87 | TMEM97 (0.52) | KDM4EHRH3TMEM97SIGMAR1ADRA1D | |
| SCHEMBL7247786 | 0.87 | SPHK2 (0.47) | LTA4HHRH3ADRA1DADRA1AADRA1B | |
| SCHEMBL7250692 | 0.87 | KDM4E (0.46) | KDM4EHRH3TMEM97SIGMAR1ADRA1D | |
| Bromide SCHEMBL7251227 | 0.86 | TMEM97 (0.51) | HRH3TMEM97SIGMAR1ADRA1DADRA1A | |
| SCHEMBL7250983 | 0.85 | TMEM97 (0.58) | KDM4EHRH3TMEM97SIGMAR1 | |
| SCHEMBL7249864 | 0.84 | HRH3 (0.51) | KDM4ELTA4HHRH3 | |
| SCHEMBL7242520 | 0.84 | SPHK2 (0.47) | LTA4HHRH3SPHK1SPHK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6534525-B1 | Method of using 2- substituted piperidine analogs as selectively active antagonist of N-methyl-D-aspartate (NMDA) receptor subtypes for treating conditions such as stroke, cerebral ischemia, central nervous system trauma, | WARNER-LAMBERT & COMPANY | 2003-03-18 | — | — | US | disclosed |
| US-6124317-A | ACTIVE DRUG TREATING STROKE, CEREBRAL ISCHEMIA, CENTRAL NERVOUS SYSTEM TRAUMA, HYPOGLYCEMIA, ANXIETY, CONVULSIONS, AMIOGLYCOSIDE ANTIBIOTICS-INDUCED HEARING LOSS, MIGRAINE HEADACHES, CHRONIC PAIN, GLAUCOMA, CMV RETINITIS, PSYCHOSIS | WARNER-LAMBERT COMPANY (US) | 2000-09-26 | — | — | US | disclosed |
| WO-1997023215-A1 | 2-SUBSTITUTED PIPERIDINE ANALOGS AND THEIR USE AS SUBTYPE-SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1997-07-03 | — | — | WO | disclosed |